We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+3.54%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.36B
AUM Growth
-$126M
Cap. Flow
+$59.8M
Cap. Flow %
2.53%
Top 10 Hldgs %
55.13%
Holding
55
New
9
Increased
3
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
NKTX icon
Nkarta
NKTX
+$85.6M
2
INZY
Inozyme Pharma
INZY
+$60.7M
3
ANNX icon
Annexon
ANNX
+$58.6M
4
MTCR
Metacrine, Inc. Common Stock
MTCR
+$31.4M
5
VRNA
Verona Pharma
VRNA
+$26.9M

Top Sells

Rank Stock Value
1
SPT icon
Sprout Social
SPT
+$109M
2
NET icon
Cloudflare
NET
+$49.6M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$44.4M
4
MRSN
Mersana Therapeutics
MRSN
+$40.4M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$5.93M

Sector Composition

Rank Sector Weight
1 Healthcare 83.55%
2 Technology 10.03%
3 Consumer Discretionary 1.95%
4 Industrials 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPT icon
1
Sprout Social
SPT
$533M
$215M 9.12%
5,596,080
-3,450,000
-38% -$109M
ALLK
2
DELISTED
Allakos
ALLK
$185M 7.82%
2,268,188
– –
ADAP
3
DELISTED
Adaptimmune Therapeutics
ADAP
$136M 5.77%
17,082,611
– –
CRSP icon
4
CRISPR Therapeutics
CRSP
$4.62B
$133M 5.63%
1,590,002
-500,676
-24% -$44.4M
OYST
5
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$125M 5.3%
5,925,287
– –
MRSN
6
DELISTED
Mersana Therapeutics
MRSN
$111M 4.7%
238,381
-80,000
-25% -$40.4M
RYTM icon
7
Rhythm Pharmaceuticals
RYTM
$7.38B
$106M 4.51%
4,912,306
– –
BDTX icon
8
Black Diamond Therapeutics
BDTX
$94.5M
$104M 4.42%
3,449,845
– –
AKUS
9
DELISTED
Akouos Inc
AKUS
$98.3M 4.16%
4,298,488
– –
NKTX icon
10
Nkarta
NKTX
$152M
$87.3M 3.7%
+2,904,974
New +$85.6M
ELVN icon
11
Enliven Therapeutics
ELVN
$3.8B
$81.7M 3.46%
1,004,293
– –
TRIL
12
DELISTED
Trillium Therapeutics Inc.
TRIL
$81.5M 3.45%
5,736,363
– –
MIRM icon
13
Mirum Pharmaceuticals
MIRM
$6.69B
$80.7M 3.42%
4,187,801
– –
AUPH icon
14
Aurinia Pharmaceuticals
AUPH
$1.93B
$76.2M 3.23%
5,172,683
– –
ANNX icon
15
Annexon
ANNX
$798M
$75.5M 3.2%
+2,497,661
New +$58.6M
ARDX icon
16
Ardelyx
ARDX
$1.25B
$71.6M 3.03%
13,633,582
– –
INZY
17
DELISTED
Inozyme Pharma
INZY
$64.3M 2.72%
+2,444,379
New +$60.7M
CSPR
18
DELISTED
Casper Sleep Inc.
CSPR
$44.8M 1.9%
6,226,130
+90
+0% +$751
GRTX
19
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$39.4M 1.67%
4,362,986
– –
VRNA
20
DELISTED
Verona Pharma
VRNA
$31.9M 1.35%
5,108,563
+3,888,889
+319% +$26.9M
MTCR
21
DELISTED
Metacrine, Inc. Common Stock
MTCR
$31.3M 1.32%
+3,062,977
New +$31.4M
CBIO
22
Crescent Biopharma
CBIO
$566M
$27.9M 1.18%
90,890
– –
LITS
23
Lite Strategy Inc
LITS
$32.4M
$26.6M 1.13%
426,654
– –
BE icon
24
Bloom Energy
BE
$48B
$24M 1.01%
1,333,333
– –
TRVI icon
25
Trevi Therapeutics
TRVI
$2.57B
$23.9M 1.01%
5,940,796
– –
1
2 3

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q3 2020 Portfolio in Review

As of Q3 2020, NEA Management Company held 55 positions worth $2.36B, down 5.1% from $2.49B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

NEA Management Company's Q3 2020 filing shows 9 new, 3 increased, 6 reduced and 1 closed positions. Its largest new stake was Nkarta: 2,904,974 shares worth $87.3M. The largest sale was Sprout Social, an estimated $109M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 79% a quarter earlier, followed by Technology and Consumer Discretionary.

  • NEA Management Company's largest Q3 2020 buy was Nkarta: 2,904,974 shares worth $87.3M.
  • NEA Management Company added most to Verona Pharma in Q3 2020, an estimated $26.9M increase.
  • NEA Management Company's biggest Q3 2020 reduction was Sprout Social, cutting an estimated $109M.
  • NEA Management Company fully exited Rigel Pharmaceuticals in Q3 2020, selling an estimated $5.93M.
  • NEA Management Company's ten largest holdings make up 55% of its $2.36B portfolio in Q3 2020.
  • NEA Management Company opened 9 new positions and closed 1 in Q3 2020.
  • NEA Management Company's portfolio value fell 5.1% quarter-over-quarter to $2.36B.

Based on NEA Management Company's 13F filing for Q3 2020, filed 6 Nov 2020.